Intra-Cellular Therapies News

This Intra-Cellular Therapies Insider Reduced Their Stake By 34%

Viewing insider transactions for Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI ) over the last year, we see that insiders were net sellers.

Simply Wall StMay 14 19:40

Buy Rating Affirmed on Intra-Cellular Therapies Amid Strong Sales and Promising Clinical Trials

TipRanksMay 10 13:18

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 9 03:44

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

Stockhouse May 8 20:00

Intra-Cellular Therapies: A Strong Buy on Robust Financials and Promising Caplyta Prospects

TipRanksMay 8 19:29

RBC Capital Remains a Buy on Intra-Cellular Therapies (ITCI)

TipRanksMay 8 18:38

Intra-Cellular Therapies Price Target Maintained With a $90.00/Share by Needham

Intra-Cellular Therapies Price Target Maintained With a $90.00/Share by Needham

Dow JonesMay 8 17:52

Intra-Cellular Therapies Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 26.39% Needham → $90 Reiterates Buy → Buy 05/07/2024 26.39% Needham → $90 Reiterates → Buy 04/2

BenzingaMay 8 17:40

Intra-Cellular Therapies: A Hold Rating Amid Anticipation of Critical Phase 3 Data and Diverse Clinical Pipeline

TipRanksMay 8 02:25

Sector Update: Health Care Stocks Steady Pre-Bell Tuesday

Health care stocks were steady pre-bell Tuesday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) both unchanged. Oscar Health (OSCR) shares were up nearly 15% af

MT NewswiresMay 7 21:18

Needham: Reiterates Intra-Cellular Therapies (ITCI.US) buy rating with a target price of $90.00.

Needham: Reiterates Intra-Cellular Therapies (ITCI.US) buy rating with a target price of $90.00.

Zhitong FinanceMay 7 20:31

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $90 Price Target

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $90 price target.

BenzingaMay 7 20:29

Intra-Cellular Therapies' Q1 Net Loss Narrows, Net Total Revenue Rises

Intra-Cellular Therapies (ITCI) reported a Q1 net loss Tuesday of $0.16 per diluted share, narrower than its loss of $0.46 a year earlier. Analysts polled by Capital IQ expected a loss of $0.33. Net t

MT NewswiresMay 7 20:16

Buy Rating Affirmed: Intra-Cellular Therapies Exceeds Q1 Expectations With Caplyta Sales Surge

TipRanksMay 7 20:14

Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q1 Revenue $144.9M

07:44 AM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q1 Revenue $144.9M

MT NewswiresMay 7 19:44

Intra-Cellular Therapies | 10-Q: Quarterly report

Futu NewsMay 7 19:44 · Announcements

Intra-cellular Therapies Reiterates Full Year 2024 Caplyta Net Product Sales Guidance Of $645M-$675M

Intra-cellular Therapies Reiterates Full Year 2024 Caplyta Net Product Sales Guidance Of $645M-$675M

BenzingaMay 7 19:33

Intra-Cellular Therapies Q1 2024 GAAP EPS $(0.16) Beats $(0.32) Estimate, Sales $144.866M Beat $141.381M Estimate

Intra-Cellular Therapies Q1 2024 GAAP EPS $(0.16) Beats $(0.32) Estimate, Sales $144.866M Beat $141.381M Estimate

BenzingaMay 7 19:32

Press Release: Intra-Cellular Therapies Reports First Quarter 2024 Financial Results

Intra-Cellular Therapies Reports First Quarter 2024 Financial Results CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53%

Dow JonesMay 7 19:30

Intra-Cellular Therapies 1Q Loss/Shr 16c >ITCI

Intra-Cellular Therapies 1Q Loss/Shr 16c >ITCI

Dow JonesMay 7 19:30